1. Partnering with Eli Lilly and Company

2. Lilly at a Glance Founded in 1876 in Indianapolis, Indiana $18.71B sales in 2007 40,600 employees worldwide Operations in 87 countries and sales in 138 countries Award winning culture: – Fortune magazine “100 best Companies to Work for” – Industry Week “100 Best-Managed Companies” – Science Magazine Best Company for Scientists – Forbes.com “The 75 most Reputable Companies in the US” Copyright © 2009 Eli Lilly and Company 2

3. Lilly Global Presence San Diego: Bioproduct R&D Indianapolis: Global R&D HQ Canada: Bioproduct Analytical R&D Australia: Drug Discovery R&D Singapore: Drug Discovery and Biomarker R&D Japan: ADME R&D China: Drug Discovery R&D Spain: Medicinal Chemistry United Kingdom: Neuroscience Research Copyright © 2009 Eli Lilly and Company 3

4. Areas of Strategic Focus Neuroscience Oncology Cardiovascular Endocrine Musculoskeletal Image and Text Copyright © 2008 Photo Researchers, Inc. All Rights Reserved. Image and Text Copyright © 2008 Photo Researchers, Inc. All Rights Reserved. Image and Text Copyright © 2008 Photo Researchers, Inc. All Rights Reserved. Copyright © 2009 Eli Lilly and Company 4

5. Key Innovation Platforms Small Molecule Antibody Peptide Protein Antisense BioProducts Copyright © 2009 Eli Lilly and Company 5

6. Lilly Recombinant Protein Products Copyright © 2009 Eli Lilly and Company 6

7. The Lilly Development Teams Copyright © 2009 Eli Lilly and Company 7

8. Neuroscience Mission Statement To improve the lives of people suffering from psychiatric and neurological disorders with innovative therapeutic advances. Copyright © 2009 Eli Lilly and Company 8

9. Neuroscience: Areas of Interest Innovative Molecules and Programs in: Schizophrenia Depression Anxiety disorders Bipolar disorders Sleep disorders Substance abuse (e.g.. Alcoholism) Cognitive dysfunction Alzheimer’s and Parkinson’s disease –Focused on approaches that affect disease progression or modification Pain –Neuropathic and inflammatory Migraine –Prophylaxis and acute treatment –Non-vasoconstrictive approaches Multiple sclerosis Copyright © 2009 Eli Lilly and Company 9

10. Lilly’s Neuroscience Clinical Development Compounds Regulatory Review Olanzapine depotDA/5-HT2 antagonistSchizophrenia Formulation Phase III NERI IVNorepinephrine reuptake inhib.Depression, ADHD DirucotideImmunological ToleranceMultiple Sclerosis LY-450139Gamma-secretase inhibitorAlzheimer’s Disease Phase II Abeta antibodyPassive immunizationAlzheimer’s Disease mGlu2/3 agonistmGlu2/3 agonistSchizophrenia LY26248035HT-2a ant. / H1 inverse agonistInsomnia mGluR3mGluR3 antagonistMigraine GRC-6211Vanilloid receptor 1 antagonistOsteoarthritic pain Phase I OPRA IIOpioid receptor antagonistAlcoholism iGluR5 antagonistiGluR5 antagonistPain Copyright © 2009 Eli Lilly and Company 10

11. Technology Needs - Neuroscience 1.Predictive biomarkers of any nature (e.g., genetic, proteomics, metabolic, other biochemical, biological, morphological) 2.Predictive animal models Copyright © 2009 Eli Lilly and Company 11

12. Lilly Knows From Experience That Partnering Supports Future Growth arzoxifene '00 ‘01 ‘02 ‘03 ‘04 ‘05 ’06 ’07 ‘08 Prasugrel enzastaurin LY-517717 LY-2181308 LY-450139 LY-2599506 LY-2624803 Arxxant TM ruboxistaurin Teplizumab Exenatide LAR NERI IV GRC-6211 MBP-8928 Eg5 Copyright © 2009 Eli Lilly and Company 12

13. External Innovation at Lilly Copyright © 2009 Eli Lilly and Company 13